The Grande lash serum lawsuit settlement resolved a proposed class action, Nixon v. Grande Cosmetics, LLC, for $6.25 million, with final approval entered on July 18, 2024, by Chief U.S. District Judge Renée Marie Bumb in the District of New Jersey.1Truthinadvertising.org. Nixon v. Grande Cosmetics Final Approval Order The suit accused Grande Cosmetics of marketing GrandeLASH-MD, GrandeBROW, and GrandeHAIR as safe cosmetics while concealing that they contain isopropyl cloprostenate (ICP), a prostaglandin analog the FDA has treated as a drug ingredient linked to eye-related side effects. Grande Cosmetics denied all wrongdoing.
What the Suit Claimed
Named plaintiff Brenda Nixon filed the complaint on November 16, 2022 (Case No. 1:22-cv-06639). The core allegation was regulatory: ICP belongs to the same chemical family found in prescription glaucoma drops and in Latisse, the only FDA-approved eyelash growth drug.2American Academy of Ophthalmology. Latisse: Eyelash Growth Drug The FDA has previously concluded that ICP-containing lash and brow products are “not safe for use except under the supervision of a practitioner licensed by law to administer them,” and in a 2011 warning letter to Lifetech Resources LLC the agency classified such products as unapproved new drugs, citing risks that included iris color change, macular edema, ocular inflammation, and interference with glaucoma therapy.3FDA Warning Letters Blog. FDA Warning Letter to Lifetech Resources LLC
Nixon argued that by selling ICP-containing serums as cosmetics, Grande was moving an unapproved drug to consumers without the warnings or oversight a drug would require. Her complaint brought claims under the New Jersey Consumer Fraud Act along with counts for fraud by misrepresentation and omission, negligent misrepresentation, breach of express and implied warranty, negligence, unjust enrichment, and the sale of an unapproved, adulterated, and misbranded drug.4ClassAction.org. Nixon v. Grande Cosmetics LLC Settlement Agreement Nixon herself reported swelling, pain, and blurred vision after using the products.
Side Effects Alleged
Court filings in the Nixon case and a related complaint listed a range of adverse effects that consumers attributed to ICP-containing serums: iris discoloration, eyelid skin darkening, ocular irritation and redness, macular edema, dry eyes, burning, itching, styes, drooping eyelids, and hair growth outside the treatment area. Some users reported lashes and brows falling out in clumps after extended use.5ClassAction.org. Ribak v. Grande Cosmetics LLC Complaint A consumer comment associated with parallel litigation described a growth in the eye that required surgical removal.6Top Class Actions. Grande Cosmetic Serums Contain Drug That Can Cause Eye Damage Class Action Alleges
Prostaglandin-based lash serums as a category have also been associated with periorbital fat loss, a hollowing around the eye socket sometimes described as “sunken eyes,” and, rarely, muscle weakness around the eye that can lead to eyelid asymmetry. Grande Cosmetics disputes that its products cause these effects, citing an independent 8-month clinical study of 120 participants which the company says found no iris color change or periorbital fat loss.7Elle. Lash Serum Prostaglandin Side Effects Risks Explained
Who Was Covered and What Claimants Received
The settlement class covered anyone who bought GrandeLASH-MD, GrandeBROW, or GrandeHAIR for personal, family, household, or professional use between January 1, 2018, and December 14, 2023. Grande officers, directors, employees, and consultants were excluded, along with government entities and judges involved in the case.8Angeion Group. Grande Cosmetics Nixon Settlement Full Notice
Class members who filed a valid claim by February 27, 2024, could receive up to $150 without proof of purchase. Those who submitted documentation of at least two separate purchases (receipts, credit card statements, or similar records) could receive an additional $150, for a total of up to $300. Final amounts depended on how many valid claims came in and on deductions for attorneys’ fees, costs, and administration, all of which came out of the $6.25 million fund. Payments were sent electronically through Venmo, Zelle, or a virtual Mastercard unless a claimant asked for a paper check.8Angeion Group. Grande Cosmetics Nixon Settlement Full Notice
The claims window has closed. Anyone learning about the case now cannot file for a payment.
Labeling Changes and the Company’s Denial
Beyond the cash fund, Grande agreed to expand the cautionary instructions on its product labeling, revise the wording of its ingredient lists for clarity, and update its website advertising.9Grande Cosmetics. Lawsuit Information The company did not reformulate. Isopropyl cloprostenate remains an ingredient in GrandeLASH-MD, which the company describes as “the gold standard for the real, undeniable results you know and love” at concentrations it considers safe.10Grande Cosmetics. Isopropyl Cloprostenate
Grande has consistently denied wrongdoing. In the official settlement notice the company stated that its serums “are safe cosmetic products with a proven track record of overwhelmingly positive consumer satisfaction” and that “comprehensive product safety testing substantiates the safety of Grande’s products.” It also pointed out that the FDA “has never alleged or found the Enhancement Serums are adulterated, misbranded or unapproved drugs.”8Angeion Group. Grande Cosmetics Nixon Settlement Full Notice On its website the company has characterized the lawsuit as concerning marketing claims rather than personal injuries and calls GrandeLASH-MD “one of the most-studied cosmetic lash serums,” citing 11 safety and performance studies.9Grande Cosmetics. Lawsuit Information
The Regulatory Backdrop
The dispute reflects a wider gap in how lash-growth ingredients are treated. Latisse, which contains the prostaglandin analog bimatoprost, is the only FDA-approved eyelash growth product and requires a prescription because of side effects that include potential permanent iris darkening, eye redness, and eyelid skin discoloration.2American Academy of Ophthalmology. Latisse: Eyelash Growth Drug Many over-the-counter serums use ICP or related prostaglandin analogs to achieve similar results while being sold as cosmetics, which do not carry the same warnings or prescription requirements.
The FDA flagged this pattern in its 2011 warning to Lifetech Resources, the maker of RapidLash and NeuLash, calling those ICP-containing products unapproved new drugs, misbranded, and potentially adulterated.3FDA Warning Letters Blog. FDA Warning Letter to Lifetech Resources LLC The agency has not taken comparable public action against Grande Cosmetics. The Nixon settlement resolved the private lawsuit but did not answer the regulatory question underneath it.